enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Mirvetuximab soravtansine - Wikipedia

   en.wikipedia.org/wiki/Mirvetuximab_soravtansine

   Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. [ 2 ] [ 5 ] Mirvetuximab soravtansine is a folate receptor alpha directed antibody and microtubule inhibitor conjugate.

3. Maropitant - Wikipedia

   en.wikipedia.org/wiki/Maropitant

   Maropitant (INN; [3] brand name: Cerenia, used as maropitant citrate , is a neurokinin-1 (NK 1) receptor antagonist developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007, for use in dogs [4] [5] and in 2012, for cats. [6]

4. FDA approves opioid-free pain medication with 'no sign of ...

   www.aol.com/news/fda-approves-opioid-free-pain...

   A new opioid-free pain medication was approved by the U.S. Food and Drug Administration (FDA) on Thursday, marking a non-addictive alternative for patients. Journavx (suzetrigine), made by Vertex ...

5. Bedinvetmab - Wikipedia

   en.wikipedia.org/wiki/Bedinvetmab

   Half the dogs received bedinvetmab and half the dogs received a sterile saline injection every 28 days for a total of three doses. [5] Before treatment and on various days throughout the study, owners used the Canine Brief Pain Inventory (CBPI) assessment tool to measure the severity of the dog's pain and the degree to which the pain interfered ...

6. FDA approves new pain medication as an alternative to opioids ...

   www.aol.com/fda-approves-pain-medication...

   The medication will be sold under the brand name Journavx for $15.50 per pill, according to Vertex Pharmaceuticals, the company that developed the new drug. The FDA's sign-off on the medication ...

7. FDA approves new type of non-opioid pain medication - AOL

   www.aol.com/fda-approves-type-non-opioid...

   The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval ...